Edoxaban Review Spurs FDA Call For Changes In Anticoagulant Trials
Executive Summary
Agency staff recommend separate assessment of ischemic and hemorrhagic strokes, and exposure-targeting of therapeutic blood levels; cardio-renal panel endorses Daiichi Sankyo’s Factor Xa inhibitor for atrial fibrillation, but concerns about reduced efficacy in normal renal function patients may result in a competitively disadvantaged label.
You may also be interested in...
BMJ’s Pradaxa Exposé Includes Wider Call For Monitoring Of All New Anticoagulants
British Medical Journal investigation focuses mainly on Boehringer’s direct thrombin inhibitor Pradaxa, but also suggests that all novel anticoagulants could benefit from testing to ensure the right anticoagulant dose is being given, for safety’s sake.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.